natgillin/translations-raw huggingface dataset:
Administer one dose of 1 ml according to the following vaccination scheme: Primary vaccination course: 1 injection from 12 weeks of age, Revaccination: 1 year after primary vaccination, then at intervals of up to 3 years. 
Prvo cijepljenje: 1 injekcija nakon 12 tjedana starosti, Revakcinacija: 1. godinu nakon prvog cijepljenja, a zatim u razmacima od po 3 godine.
Mild local and/or systemic adverse reactions related to the injection itself may be observed transitorily. 
U slučaju nehotičnog samo iniciranja prolazno se mogu pojaviti blage lokalne i/ili sistemske reakcije.
Active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection. 
Kako bi se spriječila smrtnost izazvana infekcijom virusom bjesnoće aktivno se imuniziraju mačake a stare 12 tjedana i starije.
For animal treatment only 
Samo za primjenu na životinjama.
Box of 50 vials of 1 dose. 
Kutija s 50 bočica sa po jednom dozom.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVOÐAČ(I) BIOLOŠKI DJELATNE(IH) TVARI I PROIZVOÐAČ(I) ODGOVORAN(I) ZA PUŠTANJE SERIJE U PROMET
SPECIAL STORAGE PRECAUTIONS 
11. POSEBNE MJERE PREDOSTROŽNOSTI KOD ČUVANJA
Box of 10 vials of 1 dose. 
Kutija s 10 bočica sa po jednom dozom.
Box of 2 vials of 1 dose. 
Kutija s 2 bočice sa po jednom dozom.
Memantine should not be used during pregnancy unless clearly necessary. 
Memantin ne bi trebalo upotrebljavati tijekom trudnoće, osim ako to nije izričito potrebno.
In another case of a large overdose, the patient also survived and recovered. 
U drugom slučaju predoziranja velikom dozom, bolesnik je također preživio, te se oporavio.
2 Isolated cases reported in post-marketing experience. 
2 Izolirani slučajevi prijavljeni u postmarketinškom razdoblju.
Date of latest renewal: 08 January 2018 
Datum posljednje obnove odobrenja: 8. siječnja 2018
It belongs to a group of medicines known as anti-dementia medicines. 
Spada u skupinu lijekova poznatih kao lijekovi protiv demencije.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. 
Pažljivo pročitajte cijelu uputu prije nego počnete uzimati ovaj lijek jer sadrži važne podatke za Vas.
Some factors that may raise urine pH (see section 5.2 “Elimination”) may necessitate careful monitoring of the patient. 
Neki čimbenici koji mogu povisiti pH mokraće (vidjeti dio 5.2 »Eliminacija«) mogu zahtijevati pažljivo nadziranje bolesnika.
Memantine has an absolute bioavailability of approximately 100%. 
Memantin ima apsolutnu bioraspoloživost od približno 100%.
Continue to take Memantine Mylan as long as it is of benefit to you. 
Nastavite uzimati Memantin Mylan onoliko dugo koliko od nje imate koristi.
Moderate to severe Alzheimer's disease usually causes impairment of driving performance and compromises the ability to use machinery. 
Umjerena do teška Alzheimerova bolest obično uzrokuje oštećenje sposobnosti upravljanja vozilima i kompromitira sposobnost rada na strojevima.
Your doctor will tell you whether your illness allows you to drive and to use machines safely. 
Liječnik će Vam reći dopušta li Vam bolest sigurno upravljanje vozilima i rad na strojevima.
Do not take Memantine Mylan: - if you are allergic to memantine or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Memantin Mylan: - ako ste alergični (preosjetljivi) na memantin ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6).
Children and adolescents Memantine Mylan is not recommended for children and adolescents under the age of 18 years. 
Memantin Mylan se ne preporučuje za djecu i adolescente mlađe od 18 godina.
The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4). 
Stopa bubrežne eliminacije memantina u uvjetima alkalnog urina može biti smanjena za faktor od 7 do 9 (vidjeti dio 4.4).
Memantine Mylan with food and drink 
Memantin Mylan s hranom i pićem
What Memantine Mylan is and what it is used for 
Što je Memantin Mylan i za što se koristi
This leaflet was last revised in {month YYYY}. 
Ova uputa je zadnji puta revidirana u {mjesec/GGGG}.
If you go into hospital, let your doctor know that you are taking Memantine Mylan. 
Ako dođete u bolnicu, obavijestite svog liječnika da uzimate Memantin Mylan.
Linearity Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg. 
Linearnost Ispitivanja na dobrovoljcima pokazala su linearnu farmakokinetiku u rasponu doza od 10 do 40 mg.
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Nuspojave su razvrstane prema klasifikaciji organskih sustava, koristeći sljedeću konvenciju: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
If you forget to take Memantine Mylan - If you find you have forgotten to take your dose of Memantine Mylan, wait and take your next dose at the usual time. 
Ako ste zaboravili uzeti Memantin Mylan - Ako ustanovite da ste zaboravili uzeti dozu Memantin Mylan, pričekajte i uzmite sljedeću dozu u uobičajeno vrijeme.
There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia. 
Sve je više dokaza da slabo funkcioniranje glutamatergične neurotransmisije, posebice na NMDAreceptorima, doprinosi izraženosti simptoma i progresiji bolesti kod neurodegenerativne demencije.
Package leaflet: Information for the patient 
Uputa od lijeku: Informacije za bolesnika
Memantine Mylan should be administered orally once a day and should be taken at the same time every day. 
Memantin Mylan treba primjenjivati peroralno jedanput na dan i potrebno ga je uzimati svaki dan u isto vrijeme.
- If you take a large overdose of Memantine Mylan, contact your doctor or get medical advice, as you may need medical attention. 
- Ako ste uzeli preveliku dozu Memantin Mylan, javite se Vašem liječniku za savjet, jer bi Vam mogla zatrebati medicinska pomoć.
Elevated liver function test 
Često povišeni rezultat testa jetrene funkcije
Pharmacotherapeutic group: Psychoanaleptics, other anti-dementia drugs, ATC code: N06DX01. 
Farmakoterapijska skupina: Psihoanaleptici, ostali lijekovi protiv demencije, ATK oznaka: N06DX01.
117 Allée des Parcs, 69800 Saint-Priest, France. 
117 Allée des Parcs, 69800 Saint-Priest, Francuska.
69800 Saint-Priest 
69800 Saint-Priest Francuska
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN 
POSEBNO UPOZORENJE DA LIJEK TREBA ČUVATI IZVAN DOHVATA I POGLEDA DJECE
Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted on fertility. 
Memantin nije bio teratogen kod štakora i kunića, čak ni kod maternalno toksičnih doza, a nisu zamijećeni niti štetni događaji memantina na plodnost.
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within 20 days, more than 99% being excreted renally. 
U ispitivanju u kojem je korišten oralno primijenjen 14C-memantin, uklonjeno je prosječno 84% doze unutar 20 dana, više od 99% izlučeno je putem bubrega.
Generics [UK] Limited Station Close, Potters Bar, Hertfordshire EN6 1TL, United Kingdom. 
Generics [UK] Limited Station Close, Potters Bar, Hertfordshire EN6 1TL, Ujedinjeno Kraljevstvo.
The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%). 
Nuspojave koje su se najčešće pojavljivale s većom učestalošću u skupini bolesnika liječenih memantinom nego u skupini koja je uzimala placebo bile su omaglica (6,3% naspram 5,6%), glavobolja (5,2% naspram 3,9%), konstipacija (4,6% naspram 2,6%), somnolencija (3,4% naspram 2,2%) i hipertenzija (4,1% naspram 2,8%).
Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms. 
Relativno velika predoziranja (200 mg, odnosno, 105 mg/dan tijekom 3 dana) povezana su ili samo sa simptomima umora, slabosti i/ili proljeva, ili ni sa kakvim simptoma.
What Memantine Mylan is and what it is used for What you need to know before you take Memantine Mylan How to take Memantine Mylan Possible side effects 
Što je Memantin Mylan i za što se koristi Što morate znati prije nego počnete uzimati Memantin Mylan Kako uzimati Memantin Mylan Moguće nuspojave
Maintenance treatment can be continued for as long as a therapeutic benefit is favourable and the patient tolerates treatment with memantine. 
Terapija održavanja može se nastaviti toliko dugo dok je terapijska korist povoljna, i dok bolesnik dobro podnosi liječenje memantinom.
Furthermore, memantine has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care. 
Nadalje, memantin ima blagi ili umjereni utjecaj na sposobnost upravljanja vozilima i rada na strojevima, pa ambulantne bolesnike treba upozoriti da na to obrate posebnu pozornost.
In order to reduce the risk of undesirable effects, the maintenance dose is achieved by upward titration of 5 mg per week over the first 3 weeks as follows: 
Radi smanjenja rizika od nuspojava, doza održavanja se postiže povećavanjem doze od 5 mg tjedno tijekom prva 3 tjedna na sljedeći način:
Also, Memantine Mylan may change your reactivity, making driving or operating machinery inappropriate. 
Memantin Mylan također može promijeniti Vašu sposobnost reagiranja, što čini upravljanje vozilima i rad na strojevima neprikladnima.
You may experience increased symptoms as described in section 4. 
Mogli bi Vam se javiti izraženiji simptomi opisani u dijelu 4. »Moguće nuspojave«.
Very rare (may affect up to 1 in 10,000 people): • Seizures 
Vrlo rijetke (javljaju se kod manje od 1 od 10 000 korisnika): • napadaji
The patient had received 400 mg memantine orally. 
Bolesnik je oralno uzeo 400 mg memantina.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels. 
• Ostale djelatne tvari poput cimetidina, ranitidina, prokainamida, kinidina, kinina i nikotina koje koriste isti sustav bubrežnog kationskog transporta kao i amantadin, mogli bi također stupiti u interakciju s memantinom i dovesti do potencijalnog rizika povišenja njegove koncentracije u plazmi.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Nemojte upotrebljavati ovaj lijek nakon isteka roka valjanosti navedenog na kartonskoj kutiji i blisteru nakon Rok valjanosti.
Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary. 
Istodobna primjena memantina sa spazmoliticima, dantrolenom ili baklofenom, može promijeniti njihov učinak te će možda biti potrebna prilagodba doze.
• In post-marketing experience, isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin. 
• U postmarketinškom iskustvu zabilježeni su izolirani slučajevi povišenja međunarodno ujednačenog omjera (INR-a) kod bolesnika koji su istodobno liječeni varfarinom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22 April 2013 
Datum prvog odobrenja: 22. travnja 2013.
In particular, Memantine Mylan may change the effects of the following medicines and their dose may need to be adjusted by your doctor: - amantadine, ketamine, dextromethorphan - dantrolene, baclofen - cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine - hydrochlorothiazide (or any combination with hydrochlorothiazide) - anticholinergics (substances generally used to treat movement disorders or intestinal cramps) - anticonvulsants (substances used to prevent and relieve seizures) - barbiturates (substances generally used to induce sleep) - dopaminergic agonists (substances such as L-dopa, bromocriptine) - neuroleptics (substances used in the treatment of mental disorders) - oral anticoagulants 
Posebice, Memantin Mylan može promijeniti učinak sljedećih lijekova, te će liječnik možda morati prilagoditi njihovu dozu: - amantadina, ketamina, dekstrometorfana - dantrolena, baklofena - cimetidina, ranitidina, prokainamida, kinidina, kinina, nikotina - hidroklorotiazida (ili bilo koja kombinacija s hidroklorotiazidom) - antikolinergika (lijekovi koje se uglavnom koriste za liječenje poremećaja kretanja ili crijevnih grčeva) antikonvulziva (lijekovi koji se koriste za sprječavanje i ublažavanje napadaja) - barbiturate (lijekovi koji se uglavnom koriste za uspavljivanje) - dopaminergičkih agonista (lijekovi kao što su L-dopa, bromokriptin), - neuroleptika (lijekovi koji se koriste za liječenje mentalnih poremećaja), - oralnih antikoagulansa.
Although no causal relationship has been established, close monitoring of prothrombin time or INR is advisable for patients concomitantly treated with oral anticoagulants. 
Iako uzročna povezanost nije utvrđena, preporučljivo je pažljivo praćenje protrombinskog vremena, odnosno INR-a, kod bolesnika koji se istovremeno liječe oralnim antikoagulansima.
McDermott Laboratories Ltd. T/A Gerard Laboratories Unit 35 Baldoyle Industrial Estate Grange Road 
T/A Gerard Laboratories Unit 35 Baldoyle Industrial Estate Grange Road
In the overdose cases below 140 mg or unknown dose the patients revealed symptoms from central nervous system (confusion, drowsiness, somnolence, vertigo, agitation, aggression, hallucination, and gait disturbance) and/or of gastrointestinal origin (vomiting and diarrhoea). 
U slučajevima predoziranja s dozom manjom od 140 mg ili nepoznatom dozom, bolesnici su opisivali simptome središnjeg živčanog sustava (konfuziju, uspavanost, somnolenciju, vrtoglavicu, agitaciju, agresiju, halucinacije i poremećaj hoda) i/ili gastrointestinalne simptome (povraćanje i proljev).
What you need to know before you take Memantine Mylan 
Što morate znati prije nego počnete uzimati Memantin Mylan
Talk to your doctor or pharmacist before taking Memantine Mylan - if you have a history of epileptic seizures - if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure). 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Memantin Mylan - ako u anamnezi imate epileptičke napadaje, - ako ste nedavno imali infarkt miokarda (srčani udar), ili ako bolujete od kongestivnog zatajenja srca ili nekontrolirane hipertenzije (povišeni krvni tlak).
In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine Mylan reassessed by your doctor on a regular basis. 
U tim slučajevima liječenje mora biti pažljivo nadzirano, a liječnik treba redovito ponovno procjenjivati kliničku korist od uzimanja Memantin Mylan.
The tablets can be divided into equal doses and can be taken with or without food. 
Tablete se mogu podijeliti u jednake doze i uzimati s hranom ili bez nje.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg film-coated tablets or one 20 mg film-coated tablet once a day) as described above. 
Temeljem kliničkih ispitivanja, preporučena doza za bolesnike starije od 65 godina iznosi 20 mg dnevno (dvije filmom obložene tablete od 10 mg ili jedna filmom obložena tableta od 20 mg jedanput na dan), kao što je gore opisano.
McDermott Laboratories Ltd. T/A Gerard Laboratories Unit 35 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland. 
T/A Gerard Laboratories Unit 35 Baldoyle Industrial Estate, Grange Road, Dublin 13, Irska.
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores < 20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains. 
Metaanaliza bolesnika s umjerenom do teškom Alzheimerovom bolešću (ukupni MMSE <20) iz šest placebom kontroliranih ispitivanja faze III u trajanju od 6 mjeseci (uključujući monoterapijska ispitivanja i ispitivanja s bolesnicima na stabilnoj dozi inhibitora acetilkolinesteraze) pokazala je da postoji statistički značajan učinak u korist liječenja memantinom u kognitivnom, globalnom i funkcionalnom području.
Not known (frequency cannot be estimated from the available data): • Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions 
Nepoznate učestalosti (učestalost se ne može procijeniti iz raspoloživih podataka): • upala gušterače, upala jetre (hepatitis) i psihotične reakcije
Memantine Mylan is used for the treatment of patients with moderate to severe Alzheimer's disease. 
Memantin Mylan se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.
These events have been reported in patients treated with memantine hydrochloride. 
Ovi su događaji prijavljivani kod bolesnika liječenih memantin hidrokloridom.
You can also report side effects directly via the national reporting system listed in Appendix V*. 
Nuspojave možete prijaviti i izravno putem nacionalnog sustava za prijavu nuspojava navedenog u Dodatku V.
Only limited experience with overdose is available from clinical studies and post-marketing experience. 
Iz kliničkih ispitivanja i postmarketinškog razdoblja dostupno je samo ograničeno iskustvo u vezi s predoziranjem.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity. 
U kliničkim ispitivanjima blage do teške demencije, u kojima je 1784 bolesnika liječeno memantinom, a 1595 ih je dobivalo placebo, sveukupna stopa učestalosti nuspojava u skupini liječenoj memantinom nije se razlikovala od stope učestalosti nuspojava u skupini koja je primala placebo; nuspojave su uglavnom bile blage do umjerene težine.
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer´s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)). 
Bolesnici liječeni memantinom pokazali su statistički značajno bolji učinak nego bolesnici koji su primali placebo u pogledu primarnih ishoda: skala procjene Alzheimerove bolesti (ADAS-cog) (p=0,003) i CIBIC-plus (p=0,004) u 24. tjednu liječenja (zadnje opažanje preneseno nadalje (LOCF)).
What Memantine Mylan contains - The active substance is memantine. 
Što Memantin Mylan sadrži - Djelatna tvar je memantin.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance active substance interaction of memantine with glyburide/metformin or donepezil was observed. 
U farmakokinetičkim ispitivanjima (PK) u kojima su primijenjene pojedinačne doze kod mladih zdravih ispitanika nije uočena značajna interakcija djelatna tvar-djelatna tvar između memantina i gliburida/metformina ili donepezila.
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine. 
Ako ste nedavno promijenili, ili namjeravate značajno promijeniti svoj način prehrane (npr. s normalne prehrane na strogu vegetarijansku prehranu), ili ako bolujete od stanja renalne tubularne acidoze (RTA - izrazito povećana količina tvari koje tvore kiseline u krvi zbog poremećaja rada bubrega (slaba funkcija bubrega)) ili teških infekcija mokraćnog trakta (strukture kroz koje prolazi mokraća), trebali bi obavijestiti svog liječnika, jer će Vam liječnik možda morati prilagoditi dozu lijeka.
Memantine Mylan acts on these NMDA-receptors improving the transmission of nerve signals and the memory. 
Memantin Mylan djeluje na navedene NMDA receptore poboljšavajući prijenos živčanih signala i pamćenje.
OTHER Mon → Tue → Wed → Thu → Fri → Sat → Sun 
DRUGO Pon → Uto → Sri → Čet → Pet → Sub → Ned
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study - activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002). 
U 6. mjesecu ispitivanja pokazani su povoljni učinci liječenja memantinom u usporedbi s placebom (analiza opaženih slučajeva za promjene bazirane na dojmu kliničara nakon intervjua (CIBIC-plus): p=0,025; kooperativno ispitivanje Alzheimerove bolesti - aktivnosti svakodnevnog života (ADCS-ADLsev): p=0,003; skup znakova teške onesposobljenosti (SIB): p=0,002).
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated patients as memantine-treated patients showed worsening in all three domains (21% vs. 11%, p< 0.0001). 
Kada je ustanovljeno istodobno pogoršanje stanja bolesnika u sva tri područja, rezultati su pokazali statistički značajan učinak memantina u sprječavanju pogoršanja, u skupini bolesnika liječenih placebom bilo je dvostruko više pogoršanja u sva tri područja nego u skupini bolesnika liječenih memantinom (21% naspram 11%, p<0,0001).
• Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity 
• glavobolja, pospanost, zatvor, povišeni rezultati testova jetrene funkcije, omaglica, poremećaji ravnoteže, nedostatak zraka, visoki krvni tlak i preosjetljivost na lijek.
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme. 
Kako bi se smanjio rizik od nuspojava, ta doza se postiže postupno, pridržavajući se sljedeće sheme dnevnog liječenja
Standard clinical procedures to remove active substance material, e.g. gastric lavage, carbo medicinalis (interruption of potential entero-hepatic recirculation), acidification of urine, forced diuresis should be used as appropriate. 
Treba koristiti standardne kliničke postupke za uklanjanje djelatne tvari, npr. ispiranje želuca, primjenu medicinskog ugljena (prekidanje potencijalne enterohepatičke recirkulacije), zakiseljavanje urina te forsiranu diureza, kako je prikladno.
How to take Memantine Mylan 
Kako uzimati Memantin Mylan
Memantine Mylan belongs to a group of medicines called NMDAreceptor antagonists. 
Memantin Mylan spada u skupinu lijekova poznatih kao antagonisti NMDA receptora.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Podrobnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske Agencije za lijekove http://www.ema.europa.eu.